Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Fertility preservation and ethical considerations
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Preservation is time critical but must not compromise essential treatment
Cancer and other gonadotoxic treatment can close the preservation window, yet unsafe delay to urgent disease treatment can threaten life; the decision needs rapid multidisciplinary coordination.
Action: Discuss fertility at the earliest opportunity, make an expedited referral to reproductive medicine, and agree with the treating team which option is feasible without clinically harmful delay.
Role and principles
Offer timely, equitable fertility-preservation choices before medical harm, obtain lawful informed consent, and navigate storage, donation, future-child and posthumous-use decisions transparently.
Fertility preservation separates an immediate medical threat from a possible future reproductive goal. NICE NG257 recommends discussing it when a condition or planned treatment is likely to impair fertility, at the earliest opportunity when care is urgent. The conversation should occur before treatment whenever feasible, without assuming that age, relationship, disability, sexual orientation, gender identity, parity or current uncertainty about parenthood makes future fertility unimportant.
Estimate risk from diagnosis, treatment, gonadal reserve, age and urgency. Alkylating chemotherapy, pelvic or total-body radiotherapy, gonadal surgery and some transplant regimens are important threats, but risk varies by dose and organ. The multidisciplinary team should weigh the person's prognosis, delay that preservation would cause, future treatment feasibility and the likely survival of thawed material. Give honest ranges rather than guaranteeing a future live birth.
Sperm cryopreservation is usually the fastest established option and should be offered to people of reproductive age facing likely infertility. Collect more than one sample when time and health allow, but
Assessment and patient selection
Medical preservation indication
A diagnosis or planned treatment likely to impair fertility triggers prompt discussion before therapy, including cancer, gonadal surgery, transplantation and selected autoimmune or haematological treatment.
Urgent ovarian pathway
When standard stimulation would cause harmful delay, random-start protocols or ovarian-tissue cryopreservation may be considered by the oncology-fertility multidisciplinary team.
Prepubertal pathway
Ovarian tissue is an established consideration where oocyte retrieval is impossible; testicular tissue remains experimental and needs research governance and careful consent or assent.
Consent dependency
Stored embryos require continuing effective consent from both gamete providers, whereas stored oocytes preserve options without dependence on current partner consent.
Ethical complexity
Capacity limitation, coercion, posthumous use, donor conception, surrogacy or significant future-child welfare concerns require specialist counselling and legal or ethics input.
Acute leukaemia or another disease in which ovarian stimulation would dangerously delay treatment or reintroduce malignant cells requires specialist alternatives, not routine stimulation.
Baseline assessment
01Gonadotoxicity and urgency assessmentFirst step
Why
Estimate whether fertility is threatened and how much time is safely available before treatment.
Interpretation and limitations
Combine diagnosis, drug and radiotherapy regimen, gonadal field and dose, surgery, prognosis and acceptable delay; no single reserve result determines whether discussion should occur.
02Ovarian reserve assessment
Why
Support counselling and stimulation planning when oocyte or embryo freezing is considered.
Interpretation and limitations
AMH or AFC predicts response and likely oocyte yield, not oocyte quality or eventual live birth; urgent referral should not await a result when treatment timing is tight.
03Semen assessment
Why
Plan sperm cryopreservation and future conventional IVF or ICSI needs.
Interpretation and limitations
Freeze available viable material even when parameters are abnormal if clinically appropriate; future use depends on post-thaw quality and the complete fertility context.
04Infection and procedural fitness screening
Why
Make collection, surgery, laboratory storage and future use safe.
Interpretation and limitations
Use licensed-centre virology and anaesthetic requirements and address thrombosis, bleeding or infection risk with the treating specialty.
Interventions
01Urgent referralCreate a preservation window without unsafe delayFirst stepA condition or planned treatment is likely to impair fertility.+
1Discuss future fertility and parenthood goals immediately and obtain permission for rapid reproductive-medicine referral without assuming current family plans.
2Share diagnosis, treatment regimen, urgency, infection status and prognosis between the treating team and fertility service.
3Select sperm, oocyte, embryo or ovarian-tissue preservation from anatomy, puberty, time, reserve, risk and informed preference, and document when no safe option exists.
02Informed consentMake every future use explicitGametes, embryos or tissue will be collected, created or stored.+
1Provide accessible information about procedure risk, chance of viable post-thaw material, storage cost and duration, alternatives and uncertainty, plus an offer of counselling.
Targets, monitoring and follow-up
Before gonadotoxic treatment, confirm that the referral was received, the chosen procedure occurred or a documented informed decision was made not to proceed.
After stimulation or tissue retrieval, monitor procedural recovery and ensure the treating specialty knows when essential treatment can begin.
Keep storage contact details current and respond before each 10-year consent-renewal deadline; absence of lawful consent can lead to disposal.
Review NHS-funded medical storage at least every 5 years and document whether significant infertility risk and future-use potential remain.
Before any use, recheck effective consent from every relevant gamete provider, medical fitness, donor or surrogacy requirements and the intended legal-parenthood pathway.
Special situations
Offer discussion, not a promise
Preservation protects an opportunity; thaw survival, gamete competence, future health and later treatment access mean it cannot guarantee a child.
Eggs and embryos differ ethically
Embryos provide fertilisation information but require continuing consent from both gamete providers; oocytes retain reproductive control with the person whose eggs were frozen.
Preservation eligibility is separate
NICE says conventional fertility-treatment criteria, including the lower age limit, should not be applied to NHS-funded medical preservation, although later use is assessed under current assisted-conception rules.
Storage is active consent
The 55-year legal maximum is conditional on renewal every 10 years; a clinic cannot simply keep material indefinitely on the original signature.
Identity may emerge outside the register
Home DNA testing and genetic matching can identify donors or siblings earlier or in circumstances where HFEA records do not provide identifying information, so counselling should be realistic.
Common pitfalls
01
Waiting until chemotherapy or radiotherapy has started before raising fertility, when an earlier expedited referral might have preserved options.
02
Applying relationship, parity, sexual orientation, gender identity or conventional infertility funding criteria as automatic exclusions from medical preservation discussion.
03
Presenting embryo freezing as the default without explaining mutual consent and the option of oocyte freezing.
04
Promising that stored tissue or gametes guarantee a future live birth or that stopping gender-affirming hormones will definitely restore fertility.
05
Assuming a general consent form authorises posthumous use, donation, research or use after loss of capacity without the specific required choices.
06
Failing to update clinic contact details or renew consent and discovering only later that material can no longer be stored lawfully.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Maximum lawful storage
Under current UK rules, how long can a patient's eggs, sperm or embryos generally be stored for treatment if consent remains valid?
Sources and review status8 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
do not
lose the only available window by insisting on an ideal number. When ejaculation is impossible, specialist retrieval may be considered. In prepubertal boys, testicular-tissue cryopreservation has not yet established fertility-restoration effectiveness and should be described as experimental research, not standard therapy.
Oocyte cryopreservation requires ovarian stimulation and retrieval, then vitrification of unfertilised oocytes. It preserves reproductive autonomy because future use does not depend on another current gamete provider, but success depends strongly on age at freezing and number and competence of stored oocytes. Random-start stimulation can often reduce delay. Protocol and timing must be coordinated with oncology, including hormone-sensitive disease, thrombosis, infection and anaesthetic risk.
Embryo cryopreservation is established and supplies information about fertilisation and embryo development, but embryos embody the consent of both gamete providers. Either provider may change consent before transfer, so a relationship change can make embryos unavailable even when one person wants to continue. Discuss oocyte and embryo options rather than treating embryo creation as automatically preferable for someone with a partner.
Ovarian-tissue cryopreservation removes and stores cortical tissue and can be considered when stimulation is not feasible, including before puberty or when treatment is extremely urgent. Later reimplantation aims to restore endocrine and reproductive function. It requires specialist assessment of surgical risk, follicle reserve and the possibility of reseeding malignancy; some haematological cancers make autotransplantation particularly concerning.
Preservation also matters before gender-affirming gonadectomy and should be discussed before treatments that may impair gamete production. Use anatomy- and goal-based language and recognise that delaying affirming care can itself cause harm. Evidence about recovery after stopping hormones is variable, so do not promise reversibility. The person should be able to decline preservation without having access to necessary non-fertility treatment obstructed.
NHS-funded medical preservation is assessed differently from conventional infertility treatment. NG257 says not to apply conventional eligibility criteria, including a lower age limit, to the preservation decision. However, the eligibility rules and clinical safety criteria for using stored material in assisted conception later still apply. NICE also recommends review at least every 5 years to determine whether NHS-funded storage remains necessary for a person with continuing significant infertility risk.
UK licensed treatment is governed by effective written consent. Before signing, the person must receive sufficient information and an offer of counselling. Consent covers storage duration, use in the person's or partner's treatment, donation, research or training, and what should happen after death or loss of capacity. For storage for use in treatment, gametes and embryos may be stored for up to 55 years from first storage if consent is renewed every 10 years; different limits can apply to other purposes, including embryo storage for training. Clinics need current contact details because failure to renew can make continued storage unlawful and place material at risk of disposal.
Consent is continuing, not a one-time signature. A patient, partner or donor can alter consent before insemination or embryo transfer. An embryo needs effective consent from both gamete providers for use and ordinarily for storage. If one provider withdraws consent, embryo use stops immediately and the licensed clinic may apply the statutory cooling-off period of up to 1 year while the parties reach a final decision; this is not permission to proceed with treatment. Posthumous use is possible only when the required explicit consents and named recipient arrangements were completed; surrogacy or legal-parenthood plans can require additional forms and counselling. Seek the licensed clinic and specialist legal advice rather than extrapolating from verbal wishes.
Ethical practice balances autonomy, benefit, harm, justice and the welfare of any future or existing child. The statutory welfare assessment focuses on risk of serious harm and supportive parenting and should be individual, evidence based and free from discrimination. It is not a licence to exclude single people, same-sex couples, trans people or disabled people categorically. Capacity, safeguarding and coercion require careful assessment, but unusual family structure alone is not harm.
Donation creates lifelong information implications. Treatment in a UK licensed clinic provides regulated screening, records and legal-parenthood protections. Donor-conceived people may request non-identifying information at 16 and, for an identifiable donor, identifying details at 18; modern DNA databases can reveal genetic connections earlier than legal records. Counselling should address openness with children, possible donor siblings, changing family circumstances and the donor's lack of automatic parental status in licensed treatment.
Key points
Discuss fertility preservation at the earliest opportunity with anyone whose medical condition or planned treatment is likely to impair fertility, and expedite the discussion when treatment is urgent.
Offer sperm cryopreservation to people of reproductive age at risk; offer oocyte or embryo cryopreservation as appropriate to people with ovaries of reproductive age.
Consider ovarian-tissue cryopreservation when oocyte or embryo freezing is not feasible, including before puberty; testicular-tissue cryopreservation remains experimental and belongs in research pathways.
For NHS-funded medical preservation, do not apply conventional fertility-treatment eligibility criteria, including the lower age limit; eligibility at the later time of using stored material is a separate question.
Written informed consent is legally required for use and storage, after information and an offer of counselling; embryo storage and use require effective consent from both gamete providers.
For use in treatment, gametes and embryos may be stored for up to 55 years from first storage if the patient renews storage consent every 10 years and keeps clinic contact details current.
Consent can be changed before embryo transfer or insemination; posthumous use, use after loss of capacity, donation, research and training require specific choices rather than assumed general consent.
Lack of decision-making capacity, possible coercion or uncertainty about legal parenthood requires senior, legal and safeguarding input before gametes or embryos are created or used.
Missing or expired consent can make storage or use unlawful; withdrawal prevents use and may trigger the statutory embryo-storage cooling-off period, so contact the licensed clinic urgently.
Proposed posthumous use without explicit effective consent and a properly named recipient cannot be improvised after death.
05
Capacity, consent and legal-parenthood review
Why
Ensure each use and storage decision is informed, voluntary and legally effective.
Interpretation and limitations
Clarify who provides each gamete, intended use, storage duration, withdrawal, death, incapacity, donation and parenthood; uncertainty requires specialist advice before proceeding.
06Malignant-cell contamination risk
Why
Assess whether preserved ovarian tissue could reseed disease on future reimplantation.
Interpretation and limitations
Haematological and metastatic malignancies may make autotransplantation unsafe; tissue storage does not guarantee it can later be used.
2
Record written choices for use, storage, donation, research, training, death and incapacity; for embryos obtain effective consent from both gamete providers.
3Explain the right to change consent before insemination or transfer and the need to renew storage consent every 10 years and keep contact details current.
03Long-term storageKeep consent and need under active reviewMaterial remains cryopreserved after the initial medical episode.+
1Maintain reliable contact information and respond to clinic renewal requests before each 10-year consent period ends.
2For NHS-funded medical storage, arrange review at least every 5 years and continue funding when significant infertility risk remains, in line with legislation and local process.
3Before use, reassess medical fitness, assisted-conception eligibility, relationship and consent status, material viability and current family goals.
04Ethics and future childUse individual, evidence-based deliberationDonation, posthumous use, capacity, safeguarding, surrogacy or welfare concerns complicate treatment.+
1Identify the precise legal and ethical question, separate clinical risk from value judgment and obtain specialist counselling, safeguarding, ethics or legal input as needed.
2Apply the welfare-of-the-child assessment to risk of serious harm and supportive parenting without categorical discrimination based on identity or family form.
3Discuss donor information rights, openness, legal parenthood and the realities of genetic identification before treatment proceeds in an HFEA-licensed setting.